

Contents

About the Editors	xix
List of Contributors	xx
Foreword	xxiv
Preface	xxv
Acknowledgements	xxvi

PART I

Foundations of Immunotherapy	1
-------------------------------------	----------

CHAPTER 1

History and Development of Immunotherapies – Key Breakthroughs and Milestones, from Early Immunology to Contemporary Immunotherapy	3
---	----------

Jean-Marc Cavaillon

Learning Objectives	3
1.1 Key Milestones in the History of Immunology	3
1.2 Variolation and Vaccination	6
1.3 Serotherapy	8
1.4 Anti-Tumour Activity of Bacteria, Bacterial Toxins, and Viruses	9
1.5 Immunoglobulin, Antibodies, and Monoclonal Antibodies	12
1.5.1 <i>IvIg</i>	12
1.5.2 <i>Anti-immune Cells and Anti-tumour Cells</i>	13
1.5.3 <i>Immune Checkpoint Inhibitors</i>	14
1.6 Harnessing and Targeting Cytokines	14
1.6.1 <i>A Brief History of Cytokines</i>	14
1.6.2 <i>Cytokines Used to Restore or Boost the Immune System</i>	16
1.6.3 <i>Neutralisation of Cytokines</i>	17
1.7 Targeting the Inflammatory Players	18
1.8 Cellular Therapies for Cancer	18
1.9 Neuromodulation of Inflammation	19
1.10 A Personal Concluding Remark	20

Key Terms & Definitions Sidebar	21
List of Abbreviations	21
Review Questions	22
References	22
CHAPTER 2	
Introduction to Immunology and Immune Modulation	34
<i>Janin Chandra, Lakshita Patil, and Graham Leggatt</i>	
Learning Objectives	34
2.1 The Frontlines of Immune Defence	34
2.2 Pamps and Damps	35
2.3 Complement System	35
2.4 Innate Immune Cells	35
2.5 Antigen Presentation	38
2.6 Adaptive Immunity	38
2.6.1 Development of T and B Cells	39
2.6.2 Naïve T Cell Activation	40
2.6.3 Naïve B Cell Activation	41
2.6.4 Effector T Cells	41
2.6.5 Effector B Cells and Antibody	42
2.6.6 Immunological Memory	43
2.6.7 Modulation of the Adaptive Immune Response	43
2.7 Trained Immunity – a Different Kind of Immune Memory	44
2.8 Examples of Failing Immune Regulation	44
2.8.1 Cancer	45
2.8.2 Immunopathology After Infection	45
2.8.3 Chronic Inflammatory Diseases	45
2.8.4 Autoimmune Diseases	46
2.9 Case Study – Immune Modulation Gone Wrong	46
Key Terms & Definitions Sidebar	47
List of Abbreviations	48
Review Questions	49
References	49
CHAPTER 3	
Mechanisms of Immune Evasion and Immune Surveillance: Cellular Barriers to Immunotherapy	51
<i>Marion F. Barros, Liwang Zhang, Jason J. Lee, Jenna S. Theron, Lixue Li, Shannon R. Joseph, and Fiona Simpson</i>	
Learning Objectives	51
3.1 Introduction	51
3.2 Tumour-Intrinsic Evasion Mechanisms	52
3.2.1 Major Histocompatibility Complex Class I Downregulation and Antigen Presentation Loss	52
3.2.2 Other Tumour-Intrinsic Evasion Mechanisms	54
3.2.3 Antigen Loss Under Immune Pressure	54
3.3 Tumour-Extrinsic Evasion Mechanisms	56
3.3.1 Hypoxia and HIF-1 α	56

3.3.2	<i>Extracellular Vesicles</i>	57
3.3.3	<i>Extracellular Matrix Exclusion</i>	58
3.3.4	<i>Metabolic Regulation</i>	58
3.3.5	<i>Interferon Resistance</i>	59
3.4	Parallels in Pathogens and Autoimmunity	59
3.4.1	<i>Antigenic Variation, Latency, Subversion of MHC Processing</i>	59
3.5	Evasion of the Innate Immune System	60
3.5.1	<i>NK-Cell Evasion</i>	60
3.5.2	<i>Dendritic Cell Evasion</i>	60
3.5.3	<i>Macrophage Evasion and Phenotypic Change</i>	61
	Key Terms & Definitions Sidebar	61
	List of Abbreviations	61
	Review Questions	63
	References	63

PART II

Immunotherapy in Cancer 67

CHAPTER 4

Cancer Immunotherapy: Key Concepts and Techniques 69

Denise Goh, Ng Kai Soon, Zhu Zhu, Rachel Elizabeth Ann Fincham, and Joe Yeong

	Learning Objectives	69
4.1	Introduction	69
4.2	Approaches in Cancer Immunotherapy	70
4.3	Key Concepts in Immunotherapy	71
4.3.1	<i>Cancer Immunity Cycle</i>	71
4.3.2	<i>TME Immunophenotypes</i>	71
4.3.3	<i>Cellular Components</i>	73
4.3.4	<i>Biomarker Expression</i>	73
4.4	Key Techniques for Immunotherapy Assessment	75
4.4.1	<i>Preclinical Setting</i>	75
4.4.2	<i>Clinical Setting</i>	78
4.5	Future Directions	80
	Key Terms & Definitions Sidebar	81
	List of Abbreviations	81
	Review Questions	82
	References	82

CHAPTER 5

Immune Checkpoint Inhibitors in Cancer: Mechanisms, Clinical Use, and Challenges 85

Camille Hansen and Arabella Young

	Learning Objectives	85
5.1	Introduction	85
5.2	The Discovery of Key Immune Checkpoints	87
5.2.1	<i>CTLA-4</i>	87

5.2.2	<i>PD-1/PD-L1</i>	87
5.2.3	<i>LAG-3</i>	88
5.3	Approved Indications and Biomarkers	88
5.3.1	<i>History of Clinical Approval for ICI Treatment</i>	88
5.3.2	<i>Approval Based on Tumour Mutation Rate</i>	89
5.3.3	<i>Approval Based on PD-L1 Status</i>	89
5.3.4	<i>Early-Stage Use of ICI Treatment</i>	90
5.4	Challenges and Controversies	90
5.4.1	<i>ICI Resistance</i>	90
5.4.2	<i>irAEs</i>	92
5.5	Case Studies and Real-World Examples	94
5.5.1	<i>DREAMseq Trial</i>	94
5.5.2	<i>CheckMate 816: Neoadjuvant ICI Use in Early-Stage NSCLC</i>	94
5.5.3	<i>Case Report: Neoadjuvant Triplet ICI in Glioblastoma (GBM)</i>	94
5.6	Future Directions	95
	Key Terms & Definitions Sidebar	97
	List of Abbreviations	97
	Review Questions	98
	Acknowledgements	99
	References	99

CHAPTER 6

Advancements in CAR T and CAR NK Cell Therapies

103

Karen Slattery, Thomas J. Cole, and Phillip K. Darcy

	Learning Objectives	103
6.1	Introduction	103
6.2	Armouring CAR T Cells to Enhance Therapeutic Efficacy	104
6.2.1	<i>Armouring with Pro-inflammatory Cytokines</i>	104
6.2.2	<i>Armouring with Co-stimulatory Molecules and Antibody-Like Proteins</i>	105
6.2.3	<i>Armouring with Chemokines</i>	105
6.3	Tumour-Restricted Armouring – the Next Frontier of Enhanced CAR T Cells	106
6.3.1	<i>NFAT-Mediated Tumour-Restricted Payload Delivery</i>	106
6.3.2	<i>HDR-Based Engineering for Tumour-Restricted Payload Delivery</i>	107
6.4	Engaging CAR T Cells With Endogenous Immunity	107
6.4.1	<i>CAR T Cells Secreting Bispecific Engagers (CART.BiTEs)</i>	107
6.4.2	<i>Engaging with Host APCs</i>	108
6.5	Enhancing CAR T-Cell Efficacy Through Metabolism	108
6.5.1	<i>Boosting Bioenergetics by Manipulating Nutrient Receptor Expression</i>	109
6.5.2	<i>Metabolic Reprogramming During Expansion</i>	109
6.6	Armouring CAR NK Cells for Increased Therapeutic Efficacy	110
6.6.1	<i>Pro-inflammatory Cytokines</i>	110
6.6.2	<i>Resistance to TGF-β in the TME</i>	111
6.6.3	<i>Chemokines</i>	111
6.6.4	<i>Intracellular Checkpoints</i>	111
6.6.4.1	<i>Deleting CISH to Unleash IL-15 Signalling</i>	111

6.6.5	<i>Deleting CREM to Boost NK Cell Responses</i>	112
6.7	Boosting CAR NK Cell Therapeutic Efficacy Through Metabolism	112
6.7.1	<i>Modulating Metabolism via Cytokine Signalling Pathways</i>	112
6.7.2	<i>Protecting Redox Homeostasis</i>	113
6.7.3	<i>Targeting Immunosuppressive Metabolites in the TME</i>	113
6.8	Future Directions for CAR T and CAR NK Cell Therapy	114
	Key Terms & Definitions Sidebar	114
	List of Abbreviations	114
	Review Questions	115
	References	115

CHAPTER 7

Therapeutic Cancer Vaccines: Challenges and Successes in Cancer Immunotherapy

120

Riccardo Dolcetti

	Learning Objectives	120
7.1	Introduction	120
7.2	Mechanism of Action	121
7.3	The Critical Choice of the Best Antigens for Vaccine Development	122
7.3.1	<i>Tumour-Associated Antigens (TAAs)</i>	123
7.3.2	<i>Tumour-Specific Antigens (TSAs)</i>	123
7.3.3	<i>Non-conventional or Cryptic Antigens: A New Class of Immunogenic Targets for Cancer Vaccines</i>	129
7.3.4	<i>Bacterial Peptides</i>	130
7.4	Vaccine Delivery Platforms	130
7.4.1	<i>Cell-Based Vaccines</i>	130
7.4.2	<i>Peptide-Based Vaccines</i>	131
7.4.3	<i>DNA-Based Vaccines</i>	133
7.4.4	<i>RNA-Based Vaccines</i>	133
7.4.5	<i>Bacteria-Based Vaccines</i>	134
7.5	Case Studies	135
7.5.1	<i>ISA101 + PD-1 Blockade in Incurable HPV16-Related Cancer</i>	135
7.5.2	<i>KEYNOTE-942: Personalised Neoantigen mRNA Vaccine (mRNA-4157/V940)</i>	135
7.5.3	<i>Autogene Cevumeran in Resected Pancreatic Cancer</i>	136
7.6	Current Challenges and Future Perspectives	136
7.6.1	<i>Antigen Selection and Validation: Are We Focusing on the Right Class of Antigens?</i>	136
7.6.2	<i>Tumour Heterogeneity</i>	137
7.6.3	<i>Route of Administration and DC Targeting</i>	137
7.6.4	<i>Immunosuppressive Tumour Microenvironment</i>	138
7.6.5	<i>Need for Reliable Surrogate Markers for Clinical Efficacy</i>	138
7.6.6	<i>Integration of Cancer Vaccines with Standard Therapies</i>	139
7.7	Concluding Remarks	140
	Key Terms & Definitions Sidebar	141
	List of Abbreviations	142
	Review Questions	143
	References	143

PART III**Immunotherapy in Infectious Diseases 151****CHAPTER 8****Immunotherapy for Viral Infections: Mechanisms, Clinical Applications, and Future Directions 153***Stephanie Jost, Cordelia Manickam, and R. Keith Reeves*

Learning Objectives	153
8.1 Introduction	153
8.2 Immunotherapies for Viral Infections in the Clinic	155
8.2.1 Anti-viral Antibodies	155
8.2.2 Immunomodulatory Antibodies	160
8.2.3 Interferons	161
8.2.4 Interleukins	162
8.2.5 TLR Agonists	163
8.2.6 Immune Cell Therapies	163
8.2.7 Therapeutic Vaccines	164
8.2.8 Boxed Case Studies	165
8.3 Challenges and Controversies	167
8.4 Future Directions	168
Key Terms & Definitions Sidebar	169
List of Abbreviations	170
Review Questions	171
Acknowledgements	171
References	171

CHAPTER 9**Immunotherapy for Microbial Infections: Addressing Bacterial Resistance and Parasitic Infections with Immunotherapy 179***Christian R. Engwerda and Jessica A. Engel*

Learning Objectives	179
9.1 Introduction	179
9.2 Immunotherapy for Microbial Infections	181
9.2.1 Immunological Background	181
9.2.2 Clinical Applications	182
9.3 Challenges and Limitations	185
9.4 Future Directions	186
9.5 Case Studies and Real-World Examples	188
9.5.1 Monoclonal Antibody Bezlotoxumab Neutralising <i>Clostridioides Difficile</i> Toxin B and Preventing Recurrent Infection	188
9.5.1.1 Disease Context	188
9.5.1.2 Mechanism	188
9.5.1.3 Impact	188
9.5.2 Adjunctive Interferon- γ in Drug-Resistant Pulmonary Tuberculosis	189

9.5.2.1	Disease Context	189
9.5.2.2	Mechanism	189
9.5.2.3	Impact	189
9.5.3	<i>BCG Vaccination and Trained Immunity for Protection Against Bacterial and Parasitic Infections</i>	189
9.5.3.1	Disease Context	189
9.5.3.2	Mechanism	190
9.5.3.3	Impact	190
9.5.4	<i>Anti-IL-10 Receptor Antibody Therapy in Visceral Leishmaniasis (Preclinical)</i>	190
9.5.4.1	Disease Context	190
9.5.4.2	Mechanism	190
9.5.4.3	Impact	191
9.5.5	<i>Immune Checkpoint Blockade (PD-1/PD-L1) in Malaria (Preclinical/Translational)</i>	191
9.5.5.1	Disease Context	191
9.5.5.2	Mechanism	191
9.5.5.3	Impact	191
9.5.6	<i>Type I Interferon Signalling Blockade in Malaria (Preclinical/Translational)</i>	192
9.5.6.1	Disease Context	192
9.5.6.2	Mechanism	192
9.5.6.3	Impact	192
	Key Terms & Definitions Sidebar	192
	List of Abbreviations	193
	Review Questions	196
	References	196

CHAPTER 10

Vaccine Development and Immune Response Optimisation **199** ***Limin Zhao, Jingru Gong, Ian H. Frazer, and Zhian Chen***

	Learning Objectives	199
10.1	Introduction	199
10.2	How the Immune System Responds to Vaccines	200
10.3	Next-Generation Vaccine Platforms and the Immunological Advantages	202
10.3.1	<i>VLP</i>	202
10.3.2	<i>The Era of Reverse Vaccinology</i>	204
10.3.3	<i>Synthetic Nucleotide Vaccines</i>	205
10.3.4	<i>Viral Vector Vaccine</i>	207
10.3.5	<i>Structure-Guided Vaccine Design</i>	207
10.4	Outstanding Questions in Improving Vaccine Immunity	208
	Key Terms & Definitions Sidebar	209
	List of Abbreviations	210
	Review Questions	211
	References	211

PART IV

Immunotherapy in Transplantation Settings, Autoimmune, and Inflammatory Diseases	215
---	------------

CHAPTER 11

Engineering Regulatory T Cells: Applications for Autoimmune Disorders	217
--	------------

Leonardo M.R. Ferreira and Russell W. Cochrane

Learning Objectives	217
11.1 Introduction	217
11.2 Mechanisms of Treg-Mediated Suppression	218
11.2.1 Contact-Dependent Suppression	218
11.2.2 Contact-Independent Suppression	218
11.3 Clinical Applications Across Autoimmune Diseases	220
11.3.1 Type 1 Diabetes	221
11.3.2 Systemic Lupus Erythematosus	223
11.3.3 Inflammatory Bowel Disease	224
11.3.4 Rheumatoid Arthritis	224
11.3.5 Multiple Sclerosis	224
11.3.6 Non-Treg-Based Cell Therapies	225
11.4 Challenges and Future Directions	226
Key Terms & Definitions Sidebar	228
List of Abbreviations	228
Review Questions	230
References	230

CHAPTER 12

Immunotherapy in Transplantation Settings	238
--	------------

James W. Wells

Learning Objectives	238
12.1 Introduction	238
12.2 Key Milestones in Transplant Success	240
12.2.1 Cyclosporin A	240
12.2.2 Tacrolimus	240
12.2.3 Rapamycin	240
12.2.4 Mycophenolate Mofetil	240
12.3 Clinical Applications	241
12.3.1 Immunosuppressive Regimens in Contemporary Transplant Care	241
12.3.1.1 Kidney Transplantation	241
12.3.1.2 Liver Transplantation	241
12.3.1.3 Heart Transplantation	242
12.3.2 Graft-Versus-Host Disease	242
12.3.3 Graft-Versus-Leukaemia	243

12.4	Challenges and Controversies	243
12.4.1	<i>Post-transplant Infectious Complications</i>	243
12.4.1.1	Early Period (0–30 Days)	244
12.4.1.2	Intermediate Period (1–6 Months)	244
12.4.1.3	Late Post-engraftment Period (>6 Months)	244
12.4.2	<i>Cancer Immunotherapy in Transplant Recipients</i>	245
12.4.2.1	Cancer Epidemiology	245
12.4.2.2	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients	245
12.4.2.3	Immune Checkpoint Inhibitors in HSCT Recipients	245
12.5	Future Directions	247
12.5.1	<i>Emerging Approaches for the Treatment of Transplant-Associated Skin Cancer</i>	247
12.5.1.1	Locally Counteracting the Impact of Immunosuppression in the Skin	247
12.5.1.2	Local Immune Checkpoint Therapy	247
12.5.2	<i>Xenotransplantation</i>	248
	Key Terms & Definitions Sidebar	250
	List of Abbreviations	251
	Review Questions	252
	References	253

CHAPTER 13

Immunotherapy for the Global Prevention of Haemolytic Disease of the Foetus and Newborn

259

Behnaz Heydarchi and Ian P Wicks

	Learning Objectives	259
13.1	Introduction	259
13.2	Molecular Features of RhD	261
13.2.1	<i>Structure and Function</i>	261
13.2.2	<i>Genetic Variation</i>	261
13.2.3	<i>Geographical Distribution of RhD Variants</i>	262
13.3	Evolution of Therapy for the Prevention of HDFN	262
13.3.1	<i>Early Clinical Trials of RhD-pIgG</i>	262
13.3.2	<i>Mechanism of Action of RhD-pIgG</i>	263
13.4	The Impact of HDFN	264
13.4.1	<i>Personal Perspectives From High-Income Countries</i>	264
13.4.2	<i>HDFN in Low- and Middle-Income Countries (LMICs)</i>	265
13.5	Maintaining the Supply of RhD-pIgG	265
13.6	Case Studies of Alternatives to RhD-pIgG	267
13.6.1	<i>Rozrolimupab: An Anti-RhD mAb Cocktail</i>	267
13.6.2	<i>BRAD-3: An Anti-RhD IgG3 mAb</i>	268
13.6.3	<i>FOG-1: An Anti-RhD IgG1 mAb</i>	268
13.6.4	<i>Roledumab: An Anti-RhD IgG1 mAb</i>	268
13.6.5	<i>Nipocalimab: An Anti-FcRn mAb to Reduce Maternal IgG Transfer</i>	269

13.7	Challenges in Developing a New Immunotherapy for HDFN	269
13.7.1	<i>Epitope Coverage</i>	269
13.7.2	<i>Limitations of In Vitro Assays to Predict mAb Efficacy in Clinical Trials</i>	269
13.7.3	<i>Lack of an Appropriate Animal Model of HDFN</i>	270
13.7.4	<i>mAb Safety in Pregnancy</i>	270
13.8	Future Directions	271
13.8.1	<i>Integration of AI and Machine Learning in Anti-RhD mAb Discovery</i>	271
13.8.2	<i>Development of Improved Preclinical Models of HDFN</i>	271
13.8.3	<i>Potential for Collaboration and Equitable Distribution of a Validated mAb Therapy for Global Prevention of HDFN</i>	272
	Key Terms & Definitions Sidebar	272
	List of Abbreviations	273
	Review Questions	274
	References	274

CHAPTER 14

Advances in Engineered Immune Cells: Latest Advancements in CRISPR, CAR-T, and Other Immune Cell Engineering Techniques

280

Lamberto Torralba-Raga and Karl-Johan Malmberg

	Learning Objectives	280
14.1	Introduction	280
14.2	Engineering Specificity and Functional Modalities	282
14.2.1	<i>Antigen Targeting Through CARs and TCRs</i>	282
14.2.2	<i>Functional Edits Through Modulation of Regulatory Pathways</i>	283
14.2.3	<i>Stealth Editing to Enhance Persistence</i>	284
14.3	Engineering ‘Smarter’ Cells	285
14.3.1	<i>Logic-Gated Circuits for Safer and Smarter Immune Cells</i>	285
14.3.2	<i>SynNotch Receptors for Controlled Activation</i>	286
14.3.3	<i>Switch Receptors, Converting Suppression to Activation</i>	287
14.4	Precision Engineering Tools	288
14.4.1	<i>Viral Vectors</i>	290
14.4.2	<i>Non-viral Approaches</i>	291
14.4.3	<i>Electroporation</i>	291
14.4.4	<i>Transposon Systems</i>	291
14.4.5	<i>Transient RNA Programming: mRNA and circRNA</i>	292
14.4.6	<i>Lipid and Polymeric Nanoparticles</i>	292
14.4.7	<i>Exosomes and Extracellular Vesicles</i>	292
14.4.8	<i>CRISPR Editing</i>	293
14.4.9	<i>Future-Facing Platforms</i>	294
14.5	Conclusion	294
	Key Points	295
	List of Abbreviations	296
	Review Questions	296
	References	297

PART V**Advanced Immunotherapy Techniques and Applications 303****CHAPTER 15****Personalised Immunotherapy and Biomarker-Driven Approaches 305***Naomi Berrell, Denise Goh, Clara Lawler, Meg L. Donovan, Joe Yeong, and Arutha Kulasinghe*

Learning Objectives	305
15.1 Introduction	305
15.2 Spatial Transcriptomics	307
15.3 Spatial Proteomics	309
15.4 Metabolomics	310
15.5 Epigenomics	312
15.6 Challenges and Controversies	313
15.7 Future Directions	314
15.8 Case Studies and Real-World Examples	315
Key Terms & Definitions Sidebar	315
List of Abbreviations	316
Review Questions	317
References	317

CHAPTER 16**Immunotherapy and the Microbiota: Exploring Microbiota-Immune Interactions and Their Impact on Immunotherapy Efficacy 321***Meriem Messaoudene and Marine Fidelle*

Learning Objectives	321
16.1 Introduction	321
16.2 Physiological and Immunological Functions of the Gut Microbiota	322
16.2.1 <i>Structure and Organisation of the Gut Microbiota</i>	322
16.2.2 <i>Metabolic Roles of the Gut Microbiome</i>	323
16.2.3 <i>Immunological Functions of the Gut Microbiome</i>	323
16.3 Linking the Microbiome to Immunotherapy Efficacy in Cancer	324
16.3.1 <i>Clinical Associations</i>	324
16.3.2 <i>Microbiome-Driven Mechanisms Shaping Immunotherapy Response</i>	325
16.4 Therapeutic Modulation or Protection of the Gut Microbiota to Enhance Immunotherapy Efficacy in Cancer	326
16.5 Challenges and Controversies	330
16.6 Future Directions	331
Key Terms & Definitions Sidebar	332
List of Abbreviations	332
Review Questions	333
References	333

CHAPTER 17	
Veterinary Immunotherapy	338
<i>Alexandre Humbert, Marie Abitbol, and Carole Peroz</i>	
Learning Objectives	338
17.1 Introduction	338
17.2 Monoclonal Antibodies in the Treatment of Osteoarthritis	339
17.3 Monoclonal Antibodies in the Treatment of Canine Atopic Dermatitis	342
17.4 Anticancer Immunotherapies	343
17.4.1 Cytokines-Based Strategies	343
17.4.2 Vaccination Against Human Tyrosinase in Dog Melanoma	344
17.4.3 Monoclonal Antibodies Targeting Tumour Antigens	344
17.4.4 Immune Checkpoint Inhibition	345
17.4.5 CAR-T Cells	345
17.4.6 Case-Study: Adoptive Cell Transfer Protocol Against Osteosarcoma (ECT [®] , Elias Animal Health)	345
17.5 Perspectives	346
Key Terms & Definitions Sidebar	346
List of Abbreviations	347
Review Questions	347
References	348
CHAPTER 18	
Emerging Immunotherapies and Future Horizons	352
<i>Jingchen Zhou, Jiya Jose, Matt VanBroeklin, John D. Hooper, Brett M. Paterson, and Fernando Souza-Fonseca-Guimaraes</i>	
Learning Objectives	352
18.1 Introduction	352
18.2 Core Content Sections	355
18.2.1 Bispecific/Trispecific Antibodies	355
18.2.2 Antibody–Drug Conjugates	357
18.2.3 Oncolytic Virotherapy	358
18.3 Case Study	361
18.3.1 Phase IIa Study Using Anti-Her2 Bispecific Antibody Delivered as Multimodal Therapy	361
18.3.2 AFM13-Precomplexed Allogeneic NK Cells in Refractory CD30+ Lymphoma	362
18.3.3 VG161 Oncolytic Virotherapy for Refractory Hepatocellular Carcinoma	362
18.4 Challenges and Controversies	363
18.5 Future Direction	364
Key Terms & Definitions Sidebar	365
List of Abbreviations	366
Review Questions	367
References	367
Index	372